Clinical trialNCT04850846Active, not recruitingPhase 2Interventional

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

SponsorDana-Farber Cancer InstituteEnrollment60Monoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple Myeloma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this research is to understand whether the drug metformin could be used in the future to help prevent patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) from developing multiple myeloma. The names of the study drug involved in this study is: * Metformin, extended release * Placebo ( a pill that has no active ingredients)

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Catherine R Marinac, PhD
Dana-Farber Cancer Institute
Study Director
clinicaltrials.gov ↗
Omar Nadeem, MD
Dana-Farber Cancer Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Brigham and Women'S Hospital
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Dana-Farber at Brighton
Brighton, Massachusetts, United States
Dana-Farber at Merrimack Valley
Methuen, Massachusetts, United States
Dana-Farber at Milford
Milford, Massachusetts, United States
Df/ Bwcc in Clinical Affiliation With South Shore Hospital
Weymouth, Massachusetts, United States
Dana-Farber at Nhoh
Londonderry, New Hampshire, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Metformin XR

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 27 Apr 2021
Primary completion: 29 Jan 2025
Completion: 31 Jul 2027
Last update posted: 9 Feb 2026
Registered enrollment: 60
Registry id: NCT04850846

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.